Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia

Inclusion Criteria: * Histologically confirmed CD45+ diseases: * Acute lymphoblastic leukemia or acute myeloid leukemia (AML), meeting any of the following criteria: * Primary refractory disease * Relapsed disease, defined as persistent disease following a minimum of 2 different standard chemotherapy induction attempts at time of diagnosis or at relapse * Acute myelogenous leukemia (AML), primary refractory or relapsed disease - defined as persistent disease after a minimum of two different standard chemotherapy induction attempts at time of diagnosis or relapse * Advanced myelodysplastic syndrome (MDS) defined as \> or = 15% bone marrow blasts following a minimum of one standard chemotherapy induction attempt * AML arising from preexisting MDS, refractory - defined as persistent disease following a minimum of one standard chemotherapy induction attempt * Chronic myelogenous leukemia (CML) following blast crisis (\> or = 15% marrow blasts following a minimum of one standard chemotherapy induction attempt * Peripheral leukemic blasts (by morphology) must be \< 5,000/μL (hydroxyurea to control peripheral blast count allowed) * Must have source of allogeneic stem cells (sibling, unrelated cord\[s\], or donor) identified prior to initiation of protocol therapy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 or Karnofsky PS 60-100% * Life expectancy \> 12 weeks * Total bilirubin ≤ 2.5 times upper limit of normal (ULN) * aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤ 2.5 times upper limit of normal (ULN) * Creatinine ≤ 1.3 mg/dL OR creatinine clearance ≥ 60 mL/min * Left ventricular ejection fraction (LVEF) ≥ 45% by Multi Gated Acquisition Scan (MUGA) or echocardiogram (ECHO) * Carbon Monoxide Diffusing Capacity (DLCO) (corrected) ≥ 50% of predicted * Human anti-mouse antibody (HAMA) must be negative * Not pregnant or nursing * Fertile patients must use effective contraception * Human immunodeficiency virus (HIV) negative * Recovered from all prior therapy * At least 7 days since prior biologic agents Exclusion Criteria: * Bone marrow cellularity \< 15% * Known brain metastases or active central nervous system (CNS) disease * History of allergic reactions attributed to compounds of similar chemical or biologic composition to \^90Y-AHN-12 or other agents used in study * Uncontrolled illness, including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic or congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness or social situations that would limit compliance with study requirements * Other concurrent investigational agents * Prior allogeneic transplantation * Less than 60 days since prior autologous transplantation with relapsed disease